The a16z Show

The Science and Supply of GLP-1s

58 snips
Jun 19, 2024
Brooke Boyarsky-Pratt, the CEO of KnownWell, revolutionizes the obesity medicine landscape with her personal journey battling obesity. She discusses the critical role of obesity-specific practitioners and patient-centric medical homes in fostering trust. The conversation delves into the science and impact of GLP-1 medications, highlighting their tailored applications in treatment. The challenges of cost and supply in the obesity sector are addressed, alongside a vision for a more empathetic, comprehensive approach to obesity care.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

GLP-1s Explained

  • GLP-1s mimic naturally occurring hormones, affecting insulin regulation, digestion, and fullness.
  • These therapies have been around since 2005, though recently gaining more public attention.
ANECDOTE

Early GLP-1 Awareness

  • Brooke first learned about GLP-1s in 2018 from an obesity medicine physician.
  • Dr. Fitch predicted the significant impact of GLP-1s in the future.
ADVICE

Managing GLP-1 Expectations

  • GLP-1s are effective but not a miracle cure, with varying weight loss results.
  • Manage expectations and address potential side effects like nausea with proactive measures.
Get the Snipd Podcast app to discover more snips from this episode
Get the app